Apnimed

IPO

Apnimed is a biotech company in Cambridge, United States, founded in 2017. It has raised $163.3M across 5 rounds, most recently a $79.8M Series C in January 2023.

Breathing New Life Into OSA & More

Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$163.3M
Last Round
$79.8M Series CJan 2023
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 5 funding rounds and 5 investors for this company. The full record is or through the API.

About

Apnimed is a clinical-stage biopharmaceutical company developing pharmacological treatments for obstructive sleep apnea (OSA). Founded in 2017 and headquartered in Cambridge, Massachusetts, the company's lead program AD109 is a combination of atomoxetine and oxybutynin targeting the pharyngeal muscles that cause airway collapse during sleep, offering a potential non-CPAP oral therapy for OSA.

Summary

It lists 11–50 employees. It has raised $163.3M in total across 5 rounds, most recently a $79.8M Series C round in Jan 2023. Investors include Healthcare Royalty Partners, Morningside Group and Shionogi.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
IPOJul 2026
$192.0M

Sign up to see all 7 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Apnimed on Indexed.vc
<a href="https://indexed.vc/companies/apnimed"><img src="https://indexed.vc/api/badge/company/apnimed" alt="Apnimed on Indexed.vc" width="260" height="76" /></a>